Help researchers find the cause and a cure for JM by volunteering for these important studies. Questions? Contact firstname.lastname@example.org
The Cure JM Foundation Patient Registry was created to help us build a database of Juvenile Dermatomyositis and Juvenile Polymyositis sufferers. This information will be used as part of a demographic survey to determine if there are clusters of children affected by JM in the same geographic area. The information you provide will be used exclusively for research, and will not be shared with any other organization or business not connected with this research. In addition, parents of JM patients (or adult JM patients) can also use the registration process to sign up for our Family Support Network (FSN) and Team JM (the Cure JM fundraising team). Those who register and elect to join the FSN will receive a Welcome Kit and periodic Cure JM updates.
Wanted: Patients with Juvenile Dermatomyositis, Adult Dermatomyositis, or Lupus
Either within 12 months of exposure to COVID-19 infection or 2nd dose of vaccine OR patients who have had no exposure to COVID-19 infection or vaccine.
Patients need to be seen at the NIH Clinical Center in Bethesda, Maryland, and also would return in 12 months for re-evaluation.
Patients we have seen previously in our NIH research studies are of great interest for this study.
The study requires history and physical, clinic disease assessment, questionnaires, blood work (lots of tubes drawn), and EKG, which can be completed in 1 day. For patients interested, we can also set up a blood vessel reactivity study, which requires a 2nd day for the visit.
We are also interested in enrolling healthy control subjects who have no exposure to COVID-19 infection or vaccine, and who are not related to patients with these autoimmune conditions.
Office of Patient Recruitment
800-411-1222 800-877-8339 TTY/ASII
Ask for study #000207-AR
URGENTLY NEEDED: Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
Researchers at the National Institute of Environmental Health Sciences (NIEHS) are conducting a study of Sodium Thiosulfate intravenous therapy to treat juvenile dermatomyositis and adult dermatomyositis (NCT03267277).
All patients will receive the medication sodium thiosulfate for 10 weeks in this 72-week study at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. There is no charge for treatments or testing/evaluations. Transportation within the United States and compensation are provided.
Patients must be a minimum of 7 years old and weigh at least 26 kilograms (57.3 pounds). They must have moderate to severe calcium deposits in the torso or in at least 2 limbs, with no bone fractures in the year prior to enrollment.
Eligible participants will have five visits at the NIH Clinical Center in Bethesda, Maryland, following screening for eligibility, each lasting at approximately one week. There is also a 10-week inpatient stay to provide the study medication, consisting of intravenous infusions of sodium thiosulfate 3 times a week. Study visits involve medical history and physical examinations, blood and urine tests, muscle strength and functional tests, questionnaires, and other diagnostic/imaging studies.
For more information:
- Call NIH Clinical Center Office of Patient Recruitment: 1-800-411-1222, Refer to study #17-E-0161
- Principal Investigator, Adam Schiffenbauer, M.D.: email@example.com
- Lead Associate Investigator, Lisa Rider, M.D.: firstname.lastname@example.org
- Study Coordinator, Julia Agafonova: email@example.com
- VIEW/PRINT A FLYER
URGENTLY NEEDED: Myorisk Study
Currently enrolling patients who have tested positive for Jo1 or other anti-synthetase autoantibodies, within 2 years of diagnosis. Adam Schiffenbauer, MD is the Principal Investigator, and Lisa G. Rider, MD is the Associate Investigator on this study. Please call Nastaran Bayat, the study coordinator, for more information or to enroll. Nastaran Bayat can be reached directly at (301) 451-2348 or firstname.lastname@example.org.
You can also enroll by calling (800) 411-1222.
VIEW/PRINT A FLYER
Experimental Treatment Study: H.P. Acthar Gel
Currently enrolling patients with Juvenile Dermatomyositis who are 18 years of age and older, as well as patients with the adult form of Dermatomyositis. Study participants must have refractory cutaneous symptoms, meaning that skin manifestations (calcinosis, rash, etc.) do not respond to treatment of steroids plus one other medication, such as methotrexate or IVIG. The Principal Investigator is Anthony Fernandez, MD, PhD at the Cleveland Clinic.
Enrolling adults with JDM.
A Study In Adults With Moderate To Severe Dermatomyositis
Enrolling adults with JDM or DM.
Premature Atherosclerosis in Juvenile Dermatomyositis
Study of Premature Atherosclerosis in Juvenile Dermatomyositis conducted at the Children’s Hospital at Montefiore, Bronx, NY. Currently enrolling patients age 2-21 with a diagnosis of JDM. To be eligible patients cannot be currently using medications that alter lipid metabolism or endothelial function (including lipid lowering agents), be a smoker or have another chronic illness (other than JDM), Please call (718) 696-2405.
Children with juvenile dermatomyositis (JDM) may be at increased risk of early heart disease due to risk factors including high cholesterol, abnormalities with blood sugar, high blood pressure, limited physical activity, chronic inflammation and the medications that they take. In addition, patients with JDM often have inflammation in their blood vessels which may cause the blood vessels to function improperly. Researchers have now found that dysfunctional blood vessels may be one of the first signs of early heart disease. Although it is rare, involvement of the heart and heart attacks have been reported as causes of death in cases of children and adults with dermatomyositis.
This study will use a safe ultrasound technique to examine the function of the blood vessels in children with JDM. We will also look at risk factors to see if we can identify which ones may cause the greatest risk of early heart disease in these children. With the support of Cure JM and the CARRA network, we eventually hope to perform an additional study to look at these risk factors in a large population of children with JDM and to examine the ways that we can prevent heart disease in these young children.
The long-term goal of our research is to identify which patients with JDM may be at highest risk of early heart disease and to learn if medications and dietary changes may help to prevent the development of early heart disease. In addition, the information that we gain from this study regarding the association between various risk factors and early heart disease will increase physician awareness and monitoring of these risk factors in children with JDM. Finally, by demonstrating that this safe ultrasound technique may be used as a measure of the very first signs of heart disease in children with JDM, we hope to provide physicians with a screening tool in pediatric patients with identifiable risk factors.
This study will be conducted at the Children’s Hospital at Montefiore, Bronx, NY
Dr. Dawn Wahezi, MD, MS
Children, adolescents and young adults (age 2-21 years) with a diagnosis of JDM
(1) diagnosis of a chronic illness (other than JDM) (2) current use of medications that alter lipid metabolism or endothelial function (including lipid lowering agents) and (3) current smoking.
The patient will sit in a reclining chair with the hands at heart level and propped in a comfortable position. The Endo-PAT probe will be placed gently on the fingertip. Flexible tubing connects the finger probe to the machine. Baseline measurements will be recorded over 5 minutes. Then a blood pressure cuff will be inflated for 5 minutes, followed by rapid deflation. Measurements will additionally be recorded for at least 5 minutes after deflation. The patient’s other arm will serve as a control assessment. Prior evaluation of discomfort associated with this procedure resulted in a pain score of 1 on the Wong-Baker Faces Pain Scale.